A breast cancer drug cleared brain spread in one woman
Original title: Complete Response to First-Line Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Extra-axial Central Nervous System Metastases.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This is one patient's case, not a trial, so we do not know how well it works for others.
The short version
Doctors report one woman whose cancer spread to the brain went away on a drug called T-DXd.
What was studied. This is a report on one patient, a 47-year-old woman. Her breast cancer had spread to the lining of her brain. Doctors gave her a drug called trastuzumab deruxtecan, or T-DXd.
What they found. Her nerve symptoms got much better within weeks. A scan at three months showed all the brain spots were gone. After 29 cycles, she still had no signs of brain disease as of April 2026.
What this means, and what it doesn't
What it could mean: This drug is already approved for some people with HER2-positive breast cancer. This report suggests it might also reach cancer that has spread to the brain. That is worth asking your care team about.
What it doesn't mean: This is one person's story, not a study. One case cannot show how well a drug works for other people. Using it this way for brain spread is off-label, so it is not standard care. It does not mean the drug will clear brain spread in everyone. It is not a cure. The doctors say careful trials are still needed.
Source: PubMed, September 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.